Biotechnology company
Appears in 1 story · Last updated Nov 9, 2026
Provides the ENHANZE drug-delivery technology used in RYBREVANT FASPRO; announced the FDA accelerated approval on November 6, 2026
The U.S. Food and Drug Administration granted accelerated approval on November 6 to RYBREVANT FASPRO, the subcutaneous form of amivantamab, for advanced head and neck cancer. The decision follows a 77% confirmed response rate for a first-line combination of amivantamab, pembrolizumab and carboplatin in 22 patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma, reported at ESMO 2026.
Updated 2 days ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
